Cancer immunotherapy targeting Wilms' tumor gene WT1 product

Journal of Immunology

Volumn 164, Issue 4, 2000, Pages 1873-1880

  Oka, Yoshihiro ^a   Udaka, Keiko ^b   Tsuboi, Akihiro ^a   Elisseeva, Olga A ^a   Ogawa, Hiroyasu ^a   Aozasa, Katsuyuki ^a   Kishimoto, Tadamitsu ^c   Sugiyama, Haruo ^a  

^a OSAKA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b KYOTO UNIVERSITY   (Japan)

^c OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; SYNTHETIC PEPTIDE;

ANIMAL MODEL; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CHILDHOOD CANCER; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; MOUSE; NEPHROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; SOLID TUMOR; TUMOR SUPPRESSOR GENE;

EID: 0034651735     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.164.4.1873     Document Type: Article

References (59)

1. Call, K. M., T. Glaser, C. Y. Ito, A. J. Buckler, J. Pelletier, D. A. Haber, E. A. Rose, A. Kral, H. Yeger, W. H. Lewis, et al. 1990. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 60:509.
2. Gessler, M., A. Poustka, W. Cavenee, R. L. Nevel, S. H. Orkin, and G. A. P. Bruns. 1990. Homozygous deletion in Wilms tumours of a zinc-finger gene identified by chromosome jumping. Nature 343:774.
3. Menke, A. L., A. J. Van der Eb, and A. G. Jochemsen. 1998. The Wilms' lumor I gene: oncogenc or tumor suppressor gene? Int. Rev. Cytol. 181:151.
4. + T lymphocytes, generated by mutant p21-ras (12 Val) peptide vaccination of a patient, recognize 12 Val-dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation. Int. J. Cancer 72:784.
5. Theobald, M., J. Biggs, D. Dittmer, A. J. Levine, and L. A. Sherman. 1995. Targeting p53 as a general tumor antigen. Proc. Natl. Acad. Sci. USA 92:11993.
6. Ramarathinam, L., S. Sarma, M. Maric, M. Zhao, G. Yang, L. Chen, and Y. Liu. 1995. Multiple lineages of tumors express a common tumor antigen, PIA, but they are not cross-protected. J. Immunol. 155:5323.
7. Traversari, C., P. Van der Bruggen. I. F. Luescher, C. Lurquin, P. Chomez, A. Van Pel, E. De Plaen, A. Amar-Costesec, and T. Boon. 1992. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E. J. Exp. Med. 176:1453.
8. Gaugler, B., B. Van den Eynde, P. Van der Bruggen, P. Romero, J. J. Gaforio, E. De Plaen, B. Lethe, F. Brasseur, and T. Boon. 1994. Human gene MAGE-3 codes for an antigen recognized on a melanoma by autologous cytolytic T lymphocytes. J. Exp. Med. 179:921.
9. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183: 1965.
10. Fisk, B., T. L. Blevins, J. T. Wharton, and C. G. Ioannides. 1995. Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. 181:2109.
11. Ressing, M. E., A. Sette, R. M. P. Brandt, J. Ruppert, P.A. Wentworth, M. Hartman, C. Oseroff, H. M. Grey, C. J. M. Melief, and W. M. Kast. 1995. Human CTL epitopes encoded by human papilloma virus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J. Immunol. 154:5934.
12. Inoue, K., H. Sugiyama, H. Ogawa, M. Nakagawa, T. Yamagami, H. Miwa, K. Kita, A. Hiraoka, T. Masaoka, K. Nasu, et al. 1994. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 84: 3071.
13. Inoue, K., H. Ogawa, Y. Sonoda, T. Kimura, H. Sakabe, Y. Oka, S. Miyake, H. Tamaki, Y. Oji, T. Yamagami, et al. 1997. Aberrant overexpression of the Wilms' tumor gene (WT1) in human leukemia. Blood 89:1405.
14. Miwa, H., M. Beran, and G. F. Saunders. 1992. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia 6:405.
15. Miyagi, T., H. Ahuja, T. Kubota, I. Kubonishi, H. P. Koeffler, and I. Miyoshi. 1993. Expression of the candidate Wilms tumor gene, WT1, in human leukemia cells. Leukemia 7:970.
16. Brieger, J. E. Weidmann, K. Fenchel, P. S. Mitrou, D. Hoelzer, and L. Bergmann. 1994. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia 8:2138.
17. Menssen, H. D., H. J. Renkl, U. Rodeck, J. Maurer, M. Notter, S. Schwarz, R. Reinhardt, and E. Thiel. 1995. Presence of Wilms' tumor gene (WT1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia 9:1060.
18. Yamagami, T., H. Sugiyama, K. Inoue, H. Ogawa, T. Tatekawa, M. Hirata, T, Kudoh, T. Akiyama, A. Murakami, T. Maekawa, and T. Kishimoto. 1996. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligonucleotides: Implications for the involvement of WT1 in leukemo-genesis. Blood 87:2878.
19. Inoue, K., H. Takami, H. Ogawa, Y. Oka, T. Soma, T. Tatekawa, Y. Oji, A. Tsuboi, E. H. Kim, M. Kawakami, et al. 1998. Wilms' tumor gene (WT1) competes with differentiation-inducing signal in hematopoietic progenitor cells. Blood 91:2969.
20. Tsuboi, A., Y. Oka, H. Ogawa, O. A. Elisseeva, H. Tamaki, Y. Oji, E. H. Kim, T. Soma, T. Tatekawa, M. Kawakami, et al. 1999. Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). Leuk. Res. 23:499.
21. Oji, Y., H. Ogawa, H. Tamaki, Y. Oka, A. Tsuboi, E. H. Kim, T. Soma, T. Tatekawa, M. Kawakami, M. Asada, T. Kishimoto, and H. Sugiyama. 1999. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn. J. Cancer. Res. 90:194.
22. Melief, C. J. M., and W. M. Kast. 1995. T-cell immunotherapy of tumors by adoptive transfer of cytotoxic T lymphocytes and by vaccination with minimal essential epitopes. Immunol. Rev. 145: 167.
23. Ritz, J. 1994. Tumor immunity: Will new keys unlock the door. J. Clin. Oncol. 12:217.
24. Rammensee, H.-G., T. Friede, and S. Stevanović. 1995. MHC ligands and peptide motifs: first listing. Immunogenetics 41:178.
25. Udaka, K., K.-H. Wiesmüller, S. Kienle, G. Jung, and P. Walden. 1995. Tolerance to amino acid variations in peptides binding to the MHC class I protein H-2Kb. J. Biol. Chem. 270:24130.
26. Stryn, A., L. Pedersen, T. Romme, C. B. Holm, A. Holm, and S. Buus. 1996. Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding. Eur. J. Immunol. 26:1911.
27. Ljunggren, H.-G., and K. Kärre. 1985. Host resistance directed selectively against H-2-deficient lymphoma variants. J. Exp. Med. 162:1745.
28. Lemke, H., G. J. Hämmerling, and U. Hämmerling. 1979. Fine specificity analysis with monoclonal antibodies of antigens controlled by the major histocompatibility complex and by the Qa/Tl region in mice. Immunol. Rev. 47:175.
29. Udaka, K., K.-H. Wiesmüller, S. Kienle, G. Jung, and P. Walden. 1995. Decrypting the structure of MHC-I restricted CTL epitopes with complex peptide libraries. J. Exp. Med. 181:2097.
30. Shimonkevitz, R., S. Colon, J. W. Kappler, P. Marrack, and H. M. Grey. 1984. Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J. Immunol. 133:2067.
31. Chang, C. S., L. Brossay, M. Kronenberg, and K. P. Kane. 1999. The murine nonclassical class I major histocompatibility complex-like CD1.1 molecule protects target cells from lymphokine-activated killer cell cytolysis. J. Exp. Med. 189:483.
32. Moretta, A., G. Pantaleo, L. Moretta, J. C. Cerottini, and M. C. Mingari. 1983. Direct demonstration of the clonogenic potential of every human peripheral blood T cells: clonal analysis of HLA-DR expression and cytolytic activity. J. Exp. Med. 157:743.
33. Harris, D. T., L. Jaso-Friedmann, R. B. Devlin, H. S. Koren, and D. L. Evans. 1992. The natural killer cell-like lytic activity expressed by cytolytic T lymphocytes is associated with the expression of a novel function-associated molecule. Scand. J. Immunol 35:299.
34. Mingari, M. C., C. Vitale, A. Cambiaggi, F. Schiavetti, G. Melioli, S. Ferrini, and A. Poggi 1995. Cytolytic T lymphocytes displaying natural killer (NK) - like activity: expression of NK-related functional receptors for HLA class I molecules (p58 and CD94) and inhibitory effect on the TCR-mediated target cell lysis or lymphokine production. Int. Immunol. 7:697.
35. Kozlowski, M., J. Schorey, T. Potis, V. Grigoriev, and J. Kornbluth. 1999. NK lytic-associated molecules: a novel gene selectively expressed in cells with cytolytic function. J. Immunol. 163:1775.
36. Sppeiser, D. E., M. J. Pittet, D. Valmori, R. Dunbar, D. Rimoldi, D. Lienard, H. R. MacDonald, J. C. Cerottini, V. Cerundolo, and P. Romero. 1999. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J. Exp. Med. 190:775.
37. + T cell clone. Proc. Natl. Acad. Sci. USA 90:11272.
38. Uenaka, A., T. Ono, T. Akisawa, H. Wada, T. Yasuda, and E. Nakayama. 1994. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene. J. Exp. Med. 180:1599.
39. Wu, M. X., T. J. Tsomides, and H. N. Eisen. 1995. Tissue distribution of natural peptides derived from a ubiquitous dehydrogenase, including a novel liver-specific peptide that demonstrates the pronounced specificity of low affinity T cell reactions. J. Immunol. 154:4495.
40. Nanda, N. K., K. K. Arzoo, H. M. Geysen, A. Seite, and E. E. Sercarz. 1995. Recognition of multiple peptide cores by a single T cell receptor. J Exp. Med. 182:531.
41. Udaka, K., K.-H. Wiesmüller, S. Kienle, G. Jung, and P. Walden. 1996. Self MHC-restricted peptides recognized by an alloreactive T lymphocyte clone. J. Immunol. 157:670.
42. Cheever, M. A., R. A. Kempf, and A. Fefer. 1977. Tumor neutralization, immunotherapy, and chemoimmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro. J. Immunol. 119:714.
43. Urban, J. L., and H. Schreiber. 1992, Tumor antigens. Annu. Rev. Immunol. 10:617.
44. Van den Eynde, B., and P. Van der Bruggen. 1997. T cell defined tumor antigen. Curr. Opin. Immunol. 9:684.
45. Yotnda, P., H. Firat, F. Garcia-Pons, Z. Garcia, G. Gourru, J.-P. Vemant, F. A. Lemonnier, V. Leblond, and P. Langlade-Demoyen. 1998. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest. 101:2290.
46. Yotnda, P. F. Garcia, M. Peuchmaur, B. Grandchamp, M. Duval, F. Lemonnier, E. Vilmer, and P. Langlade-Demoyen. 1998. Cytotoxic T cell response against the chimeric ETV6-AML1 childhood acute lymphoblastic leukemia. J. Clin. Invest. 102:455.
47. Tamaki, H., H. Ogawa, K. Inoue, T. Soma, T. Yamagami, S. Miyake, Y. Oka, Y. Oji, T. Tatekawa, A. Tsuboi, et al. 1996. Increased expression of the Wilms tumor gene (WT1) at relapse in acute leukemia. Blood 88:4396.
48. Kappler, J. W., N. Roehm, and P. Marrack. 1987. T cell tolerance by clonal elimination in the thymus. Cell 49:273.
49. Webbs, S., C. Morris, and J. Sprent. 1990. Extrathymic tolerance of mature T cells: clonal elimination as a consequence of immunity. Cell 63:1249.
50. Burke, L. C., D. Lo, O. Kanagawa, R. Brinster, and R. A. Flavell. 1989. T-cell tolerance by clonal anergy in transgenic mice with nonlymphoid expression of MHC class II I-E. Nature 342:564.
51. Schönrich, G., U. Kalinke, F. Momburg, M. Malissen, A.-M. Schmitt-Verhulst, B. Malissen, G. Hämmerling, and B. Arnold. 1991. Down-regulation of T cell receptors on self-reactive T cells as a novel mechanism for extrathymic tolerance induction. Cell 65:293.
52. Mackay, C. R. 1993. Homing of native, memory and effector lymphocytes. Curr. Opin. Immunol. 5:423.
53. Ohashi, P. S., S. Oehlen, K. Buerki, H. Pircher. C. T. Ohashi, B. Odermatt, and B. Malissen. 1991. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65:305.
54. Oldstone, M. B., M. Nerenberg, P. Southern, J. Price, and H. Lewicki. 1991. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 65:319.
55. Heath, W. R., F. Karamalis, J. Donoghue, and J. F. Miller. 1995. Autoimmunity caused by ignorant CD8+ T cells is transient and depends on avidity. J. Immunol. 155:2339.
56. Dyall, R., W. B. Bowne, L. W. Weber, J. LeMaoult, P. Szabo, Y. Moroi, G. Piskun, J. J. Lewis, A. N. Houghton, and J. Nikolic-Zugic. 1998. Heteroclitic immunization induces tumor immunity. J. Exp. Med. 188:1553.
57. Kaneko, T., T. Moriyama, K. Udaka, K. Hiroishi, H. Kita, H. Okamoto, H. Yagita, K. Okumura, and M. Imawari. 1997. Impaired induction of cytotoxic T lymphocytes by antagonism of a weak agonist borne by a variant hepatitis C virus epitope. Eur. J. Immunol. 27:1782.
58. + T cells. J. Exp. Med. 186:239.
59. Oka, Y., O. A. Elisseeva, A. Tsuboi, H. Ogawa, H. Tamaki, H. Li, Y. Oji, E. H. Kim, T. Soma, M. Asada, et al. Human cytotoxic T lymphocyte responses specific for peptides of wild-type Wilms' tumor gene WT1 product. Immunogenetics, In press.